Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Oligonucleotides, Antisense"" wg kryterium: Temat


Tytuł:
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
Autorzy:
Chen S; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
Heendeniya SN; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
Le BT; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.; ProGenis Pharmaceuticals Pty Ltd, Bentley, WA, 6102, Australia.
Rahimizadeh K; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
Rabiee N; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
Zahra QUA; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
Veedu RN; Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia. .; Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia. .; ProGenis Pharmaceuticals Pty Ltd, Bentley, WA, 6102, Australia. .
Pokaż więcej
Źródło:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2024 Mar; Vol. 38 (2), pp. 177-203. Date of Electronic Publication: 2024 Jan 22.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/therapeutic use
Oligonucleotides, Antisense*/pharmacology
Metabolic Diseases*/drug therapy
Metabolic Diseases*/genetics
United States ; Humans ; Oligonucleotides/therapeutic use
Czasopismo naukowe
Tytuł:
Understanding Antisense Oligonucleotide Efficiency in Inhibiting Prokaryotic Gene Expression.
Autorzy:
Story S; NUBAD, LLC, Greenville, South Carolina 29605, United States.
Bhaduri S; NUBAD, LLC, Greenville, South Carolina 29605, United States.
Ganguly S; Laboratory of Medicinal Chemistry, Department of Chemistry, Clemson University, Clemson, South Carolina 29634, United States.
Dakarapu R; NUBAD, LLC, Greenville, South Carolina 29605, United States.
Wicks SL; NUBAD, LLC, Greenville, South Carolina 29605, United States.
Bhadra J; Laboratory of Medicinal Chemistry, Department of Chemistry, Clemson University, Clemson, South Carolina 29634, United States.
Kwange S; NUBAD, LLC, Greenville, South Carolina 29605, United States.
Arya DP; Laboratory of Medicinal Chemistry, Department of Chemistry, Clemson University, Clemson, South Carolina 29634, United States.; NUBAD, LLC, Greenville, South Carolina 29605, United States.
Pokaż więcej
Źródło:
ACS infectious diseases [ACS Infect Dis] 2024 Mar 08; Vol. 10 (3), pp. 971-987. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Escherichia coli*/genetics
Escherichia coli*/metabolism
Oligonucleotides ; Morpholinos ; RNA/chemistry ; RNA/metabolism ; Gene Expression
Czasopismo naukowe
Tytuł:
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Autorzy:
Hu Y; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Revenko A; Ionis Pharmaceuticals, Carlsbad, CA, 92008, USA.
Barsoumian H; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bertolet G; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fowlkes NW; Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maazi H; Ionis Pharmaceuticals, Carlsbad, CA, 92008, USA.
Green MM; Department of Veterinary Medicine & Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
He K; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Sezen D; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey.
Voss TA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Leyton CSK; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Masrorpour F; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rafiq Z; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Puebla-Osorio N; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Leuschner C; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
MacLeod R; Ionis Pharmaceuticals, Carlsbad, CA, 92008, USA.
Cortez MA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Welsh JW; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 06; Vol. 43 (1), pp. 70. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/pharmacology
Radioimmunotherapy*
Female ; Animals ; Mice ; CD8-Positive T-Lymphocytes ; c-Mer Tyrosine Kinase/genetics ; Proto-Oncogenes ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Hydrophobicity Tuning of Cationic Polyaspartamide Derivatives for Enhanced Antisense Oligonucleotide Delivery.
Autorzy:
Yum J; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.; Nucleotide and Peptide Drug Discovery Center (TIDE Center), Institute of Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan.
Aulia F; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Kamiya K; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Hori M; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Qiao N; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Kim BS; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Naito M; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Ogura S; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Nagata T; Nucleotide and Peptide Drug Discovery Center (TIDE Center), Institute of Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan.
Yokota T; Nucleotide and Peptide Drug Discovery Center (TIDE Center), Institute of Research, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-0034, Japan.
Uchida S; Department of Advanced Nanomedical Engineering, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
Obika S; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.
Kim HJ; Department of Biological Engineering, College of Engineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea.; Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea.
Miyata K; Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.; Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Pokaż więcej
Źródło:
Bioconjugate chemistry [Bioconjug Chem] 2024 Feb 21; Vol. 35 (2), pp. 125-131. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Oligonucleotides, Antisense*
Polymers*/chemistry
Czasopismo naukowe
Tytuł:
Hoechst-Modification on Oligodeoxynucleotides for Efficient Transport to the Cell Nucleus and Gene Regulation.
Autorzy:
Makanai H; Department of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University, 5-10-1 Fuchinobe, Chuo-ku, Sagamihara, 252-5258, Japan.
Nishihara T; Department of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University, 5-10-1 Fuchinobe, Chuo-ku, Sagamihara, 252-5258, Japan.
Nishikawa M; Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba, 278-8510, Japan.
Tanabe K; Department of Chemistry and Biological Science, College of Science and Engineering, Aoyama Gakuin University, 5-10-1 Fuchinobe, Chuo-ku, Sagamihara, 252-5258, Japan.
Pokaż więcej
Źródło:
Chembiochem : a European journal of chemical biology [Chembiochem] 2024 Feb 01; Vol. 25 (3), pp. e202300645. Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/metabolism
Oligodeoxyribonucleotides*/genetics
Oligodeoxyribonucleotides*/metabolism
DNA/genetics ; DNA/metabolism ; Cell Nucleus/metabolism
Czasopismo naukowe
Tytuł:
A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity.
Autorzy:
Byrnes AE; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Roudnicky F; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Gogineni A; Department of Translational Imaging, Genentech, Inc., South San Francisco, CA 94080, USA.
Soung AL; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Xiong M; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Hayne M; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Heaster-Ford T; Department of Translational Imaging, Genentech, Inc., South San Francisco, CA 94080, USA.
Shatz-Binder W; Pharmaceutical Development, Genentech, Inc., South San Francisco, CA 94080, USA.
Dominguez SL; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Imperio J; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Gierke S; Department of Pathology, Genentech, Inc., South San Francisco, CA 94080, USA; Center for Advanced Light Microscopy, Genentech, Inc., South San Francisco, CA 94080, USA.
Roberts J; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Guo J; Department of Cancer Immunology, Genentech, Inc., South San Francisco, CA 94080, USA.
Ghosh S; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Yu C; Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA.
Roose-Girma M; Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA.
Elstrott J; Department of Translational Imaging, Genentech, Inc., South San Francisco, CA 94080, USA.
Easton A; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA.
Hoogenraad CC; Department of Neuroscience, Genentech, Inc., South San Francisco, CA 94080, USA. Electronic address: .
Pokaż więcej
Źródło:
Cell reports methods [Cell Rep Methods] 2024 Jan 22; Vol. 4 (1), pp. 100673. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*
Oligonucleotides*
Mice ; Animals ; Liver/metabolism ; Administration, Intravenous ; Coloring Agents/metabolism
Czasopismo naukowe
Tytuł:
An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3.
Autorzy:
Wang X; State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University Wuhan 430072, China. Electronic address: .
Yan L; State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University Wuhan 430072, China.
Guo J; State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University Wuhan 430072, China; Department of Endodontics, School & Hospital of Stomatology, Wuhan University, Wuhan 430072, China. Electronic address: .
Jia R; State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University Wuhan 430072, China. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2024 Jan 05; Vol. 126, pp. 111280. Date of Electronic Publication: 2023 Dec 04.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*
Programmed Cell Death 1 Receptor*/genetics
Humans ; Alternative Splicing ; Exons/genetics ; Protein Isoforms/genetics ; Serine-Arginine Splicing Factors/genetics
Czasopismo naukowe
Tytuł:
Injectable Biodegradable Silica Depot for Controlled Subcutaneous Delivery of Antisense Oligonucleotides with beyond Monthly Administration.
Autorzy:
McGowan A; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.
Gennemark P; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.; Department of Biomedical Engineering, Linköping University, Linköping 581 83, Sweden.
Akieh-Pirkanniemi M; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.
Wirman L; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.
Davies N; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Elebring M; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Tivesten A; CVRM CMC Projects, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Strimfors M; Bioscience metabolism, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Hölttä M; Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Söderberg M; Pathology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Berntsson V; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Balas D; Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Koskinen M; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.
Leino L; DelSiTech Ltd., PharmaCity, Itäinen Pitkäkatu 4 B, 20520 Turku, Finland.
Abrahmsén-Alami S; Sustainable Innovation & Transformational Excellence, Pharmaceutical Technology & Development, Operations, AstraZeneca, Mölndal, Gothenburg SE-431 83, Sweden.
Pokaż więcej
Źródło:
Molecular pharmaceutics [Mol Pharm] 2024 Jan 01; Vol. 21 (1), pp. 143-151. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*
Liver*/metabolism
Humans ; Rats ; Animals ; Injections
Czasopismo naukowe
Tytuł:
Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry.
Autorzy:
Terada C; Department of Chemistry of Biofunctional Molecules, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.; JSPS Research Fellow (DC1), Japan Society for the Promotion of Science, Tokyo, Japan.
Oh K; Department of Chemistry of Biofunctional Molecules, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Tsubaki R; Department of Chemistry of Biofunctional Molecules, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Chan B; Graduate School of Engineering, Nagasaki University, Nagasaki, Japan.
Aibara N; Department of Pharmacy Practice, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Ohyama K; Department of Molecular Pathochemistry, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Shibata MA; Department of Anatomy and Cell Biology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Wada T; Institute of Multidisciplinary Research for Advanced Materials (IMRAM), Tohoku University, Sendai, Miyagi, Japan.
Harada-Shiba M; Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan.; Cardiovascular Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Yamayoshi A; Department of Chemistry of Biofunctional Molecules, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Yamamoto T; Department of Chemistry of Biofunctional Molecules, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2023 Dec 02; Vol. 14 (1), pp. 7972. Date of Electronic Publication: 2023 Dec 02.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Oligonucleotides, Antisense*/metabolism
Peptide Nucleic Acids*
Male ; Humans ; RNA/metabolism ; Protein Binding ; Nucleic Acid Hybridization ; Phosphorothioate Oligonucleotides/chemistry
Czasopismo naukowe
Tytuł:
RNA-Based Strategies for Cancer Therapy: In Silico Design and Evaluation of ASOs for Targeted Exon Skipping.
Autorzy:
Pacelli C; Department of Biochemical Sciences 'A. Rossi Fanelli', Sapienza University of Rome, 00185 Rome, Italy.
Rossi A; Section of Oncology, Department of Medicine, University of Verona-School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.
Milella M; Section of Oncology, Department of Medicine, University of Verona-School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.
Colombo T; Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), 00185 Rome, Italy.
Le Pera L; Core Facilities, Italian National Institute of Health (ISS), 00161 Rome, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 03; Vol. 24 (19). Date of Electronic Publication: 2023 Oct 03.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Oligonucleotides, Antisense*/therapeutic use
Neoplasms*/therapy
Neoplasms*/drug therapy
Humans ; RNA ; RNA Splicing ; Exons/genetics
Czasopismo naukowe
Tytuł:
Antiviral Efficacy of RNase H-Dependent Gapmer Antisense Oligonucleotides against Japanese Encephalitis Virus.
Autorzy:
Okamoto S; Laboratory of Preventive Veterinary Medicine and Animal Health, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.; Nihon University Veterinary Research Center, Fujisawa, Kanagawa 252-0880, Japan.
Echigoya Y; Nihon University Veterinary Research Center, Fujisawa, Kanagawa 252-0880, Japan.; Laboratory of Biomedical Science, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.
Tago A; Nihon University Veterinary Research Center, Fujisawa, Kanagawa 252-0880, Japan.; Laboratory of Biomedical Science, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.
Segawa T; Laboratory of Preventive Veterinary Medicine and Animal Health, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.; Nihon University Veterinary Research Center, Fujisawa, Kanagawa 252-0880, Japan.
Sato Y; Nihon University Veterinary Research Center, Fujisawa, Kanagawa 252-0880, Japan.; Laboratory of Biomedical Science, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.
Itou T; Laboratory of Preventive Veterinary Medicine and Animal Health, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-0880, Japan.; Nihon University Veterinary Research Center, Fujisawa, Kanagawa 252-0880, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Oct 02; Vol. 24 (19). Date of Electronic Publication: 2023 Oct 02.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Oligonucleotides, Antisense*/pharmacology
Oligonucleotides, Antisense*/metabolism
Encephalitis Virus, Japanese*/genetics
Encephalitis Virus, Japanese*/metabolism
Animals ; Chlorocebus aethiops ; Humans ; Ribonuclease H/metabolism ; Vero Cells ; RNA, Viral/genetics ; Antiviral Agents/pharmacology
Czasopismo naukowe
Tytuł:
Antisense oligonucleotides targeting the miR-29b binding site in the GRN mRNA increase progranulin translation.
Autorzy:
Aggarwal G; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA.
Banerjee S; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA.
Jones SA; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA.
Benchaar Y; Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, Laval University, Quebec City, Quebec, Canada.
Bélanger J; Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, Laval University, Quebec City, Quebec, Canada.
Sévigny M; Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, Laval University, Quebec City, Quebec, Canada.
Smith DM; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA.
Niehoff ML; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Veterans Affairs Medical Center, St Louis, Missouri, USA.
Pavlack M; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA.
de Vera IMS; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA.
Petkau TL; Department of Medical Genetics, Centre for Molecular Medicine & Therapeutics, B.C. Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Leavitt BR; Department of Medical Genetics, Centre for Molecular Medicine & Therapeutics, B.C. Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Division of Neurology, Department of Medicine, University of British Columbia Hospital, Vancouver, British Columbia, Canada; Center for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
Ling K; Ionis Pharmaceuticals, Carlsbad, California, USA.
Jafar-Nejad P; Ionis Pharmaceuticals, Carlsbad, California, USA.
Rigo F; Ionis Pharmaceuticals, Carlsbad, California, USA.
Morley JE; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA.
Farr SA; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA; Veterans Affairs Medical Center, St Louis, Missouri, USA.
Dutchak PA; Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, Laval University, Quebec City, Quebec, Canada.
Sephton CF; Department of Psychiatry and Neuroscience, CERVO Brain Research Centre, Laval University, Quebec City, Quebec, Canada.
Nguyen AD; Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA; Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St Louis, Missouri, USA; Institute for Translational Neuroscience, Saint Louis University, St Louis, Missouri, USA. Electronic address: .
Pokaż więcej
Źródło:
The Journal of biological chemistry [J Biol Chem] 2023 Dec; Vol. 299 (12), pp. 105475. Date of Electronic Publication: 2023 Nov 18.
Typ publikacji:
Journal Article
MeSH Terms:
Frontotemporal Dementia*/genetics
MicroRNAs*/genetics
Oligonucleotides, Antisense*/genetics
Progranulins*/genetics
Animals ; Humans ; Mice ; 3' Untranslated Regions ; Binding Sites ; Intercellular Signaling Peptides and Proteins/genetics ; Mutation ; RNA, Messenger/genetics
Czasopismo naukowe
Tytuł:
Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic Properties.
Autorzy:
Sela T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.; Department of Biochemistry, Ludwig-Maximilians-Universität, Munich 80539, Germany.
Mansø M; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd., Fremtidsvej 3, Hørsholm 2970, Denmark.
Siegel M; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Marban-Doran C; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Ducret A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Niewöhner J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Ravn J; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd., Fremtidsvej 3, Hørsholm 2970, Denmark.
Martin RE; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Sommer A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Lohmann S; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Krippendorff BF; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Ladefoged M; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd., Fremtidsvej 3, Hørsholm 2970, Denmark.
Indlekofer A; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Quaiser T; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Bueddefeld F; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Koller E; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Mohamed MY; Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Oelschlaegel T; Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Gothelf KV; Department of Chemistry and Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Aarhus 8000, Central Denmark Region, Denmark.
Hofer K; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Roche Diagnostics GmbH, Nonnenwald 2, Penzberg 82377, Germany.
Schumacher FF; Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel 4070, Switzerland.
Pokaż więcej
Źródło:
Bioconjugate chemistry [Bioconjug Chem] 2023 Nov 15; Vol. 34 (11), pp. 2096-2111. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Oligonucleotides, Antisense*/chemistry
Antibodies*
Oligonucleotides ; Peptides
Czasopismo naukowe
Tytuł:
In-silico study of antisense oligonucleotide antibiotics.
Autorzy:
Chen ES; Biology, Lafayette College, Easton, PA, United States.
Ho ES; Biology, Lafayette College, Easton, PA, United States.
Pokaż więcej
Źródło:
PeerJ [PeerJ] 2023 Nov 15; Vol. 11, pp. e16343. Date of Electronic Publication: 2023 Nov 15 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Anti-Bacterial Agents*/pharmacology
Staphylococcus aureus/genetics ; Oligonucleotides
Czasopismo naukowe
Tytuł:
Sequencing of Morpholino Antisense Oligonucleotides Using Electron Capture Dissociation Mass Spectrometry.
Autorzy:
Karasawa K; SCIEX, 4-7-35 Kitashinagawa, Shinagawa, Tokyo 140-0001, Japan.
Duchoslav E; SCIEX, 71 Four Valley Drive, Concord, Ontario L4K 4 V8, Canada.
Burton L; SCIEX, 71 Four Valley Drive, Concord, Ontario L4K 4 V8, Canada.
Kawakami J; Konan University, 8-9-1 Okamoto, Higashinada-ku, Kobe, Hyogo 658-8501, Japan.
Baba T; SCIEX, 71 Four Valley Drive, Concord, Ontario L4K 4 V8, Canada.
Pokaż więcej
Źródło:
Analytical chemistry [Anal Chem] 2023 Nov 07; Vol. 95 (44), pp. 16352-16358. Date of Electronic Publication: 2023 Oct 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Oligonucleotides, Antisense*
Electrons*
Morpholinos ; Tandem Mass Spectrometry/methods ; Ions/chemistry
Czasopismo naukowe
Tytuł:
Antisense Oligonucleotide Activation via Enzymatic Antibiotic Resistance Mechanism.
Autorzy:
Darrah KE; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Albright S; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Kumbhare R; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Tsang M; Department of Developmental Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Chen JK; Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, United States.
Deiters A; Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
Pokaż więcej
Źródło:
ACS chemical biology [ACS Chem Biol] 2023 Oct 20; Vol. 18 (10), pp. 2176-2182. Date of Electronic Publication: 2023 Jun 16.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Oligonucleotides, Antisense*/pharmacology
Zebrafish*/genetics
Animals ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/metabolism ; Cephalosporins/metabolism ; beta-Lactamases/metabolism ; Bacteria/metabolism ; Drug Resistance, Microbial ; Gene Expression ; beta-Lactamase Inhibitors ; Microbial Sensitivity Tests ; Mammals/genetics ; Mammals/metabolism
Czasopismo naukowe
Tytuł:
Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.
Autorzy:
Leitão ADG; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Ahammad RU; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Spencer B; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.
Wu C; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America; Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA 92121, United States of America.
Masliah E; Laboratory of Neurogenetics, National Institute of Aging, National Institute of Health, Bethesda, MD 20892, United States of America.
Rissman RA; Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America; Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA 92121, United States of America; VA San Diego Healthcare System, San Diego, CA 92161, United States of America. Electronic address: .
Pokaż więcej
Źródło:
Neurobiology of disease [Neurobiol Dis] 2023 Oct 01; Vol. 186, pp. 106285. Date of Electronic Publication: 2023 Sep 09.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Oligonucleotides, Antisense*/pharmacology
Alzheimer Disease*/drug therapy
Animals ; Mice ; alpha-Synuclein/genetics ; Amyloid beta-Peptides ; Apolipoproteins B ; Disease Models, Animal
Czasopismo naukowe
Tytuł:
Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin-2.
Autorzy:
Horie S; Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Suzuki Y; Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.; New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.
Yamamoto T; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Obika S; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Mohri K; Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
Kiyota C; Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
Ren Q; Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
Warashina S; Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
Wada Y; Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
Watanabe Y; Laboratory for Pathophysiological and Health Science, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
Mukai H; Laboratory for Molecular Delivery and Imaging Technology, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.; Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Sato Y; Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.; New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.
Pokaż więcej
Źródło:
Cancer science [Cancer Sci] 2023 Sep; Vol. 114 (9), pp. 3740-3749. Date of Electronic Publication: 2023 Jul 10.
Typ publikacji:
Journal Article
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Oligonucleotides, Antisense*/pharmacology
Oligonucleotides, Antisense*/therapeutic use
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Humans ; Cell Line ; Transcription Factors ; Oligonucleotides/pharmacology ; Oligonucleotides/therapeutic use ; Cell Cycle Proteins/genetics ; Angiogenic Proteins
Czasopismo naukowe
Tytuł:
Identifying Antisense Oligonucleotides to Disrupt Small RNA Regulated Antibiotic Resistance via a Cell-Free Transcription-Translation Platform.
Autorzy:
Tsai MJ; Department of Biology, California State University Northridge, Northridge, California 91330, United States.
Zambrano RAI; Department of Biology, California State University Northridge, Northridge, California 91330, United States.; Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island 02912, United States.
Susas JL; Department of Biology, California State University Northridge, Northridge, California 91330, United States.
Silva L; Department of Biology, California State University Northridge, Northridge, California 91330, United States.
Takahashi MK; Department of Biology, California State University Northridge, Northridge, California 91330, United States.
Pokaż więcej
Źródło:
ACS synthetic biology [ACS Synth Biol] 2023 Aug 18; Vol. 12 (8), pp. 2245-2251. Date of Electronic Publication: 2023 Aug 04.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural
MeSH Terms:
Oligonucleotides, Antisense*/genetics
Oligonucleotides, Antisense*/pharmacology
Oligonucleotides, Antisense*/metabolism
Escherichia coli*/genetics
RNA, Bacterial/genetics ; Drug Resistance, Microbial ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/metabolism
Raport
Tytuł:
A single-cell map of antisense oligonucleotide activity in the brain.
Autorzy:
Mortberg MA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gentile JE; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Nadaf NM; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Vanderburg C; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Simmons S; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Dubinsky D; Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
Slamin A; Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
Maldonado S; Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
Petersen CL; Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
Jones N; Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
Kordasiewicz HB; Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.
Zhao HT; Ionis Pharmaceuticals, Carlsbad, CA 92010, USA.
Vallabh SM; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.; Department of Neurology, Harvard Medical School, Boston, MA02115, USA.; Prion Alliance, Cambridge, MA 02139, USA.
Minikel EV; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.; Department of Neurology, Harvard Medical School, Boston, MA02115, USA.; Prion Alliance, Cambridge, MA 02139, USA.
Pokaż więcej
Źródło:
Nucleic acids research [Nucleic Acids Res] 2023 Aug 11; Vol. 51 (14), pp. 7109-7124.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Brain*/drug effects
Brain*/metabolism
Oligonucleotides, Antisense*/administration & dosage
Oligonucleotides, Antisense*/analysis
Animals ; Mice ; Oligonucleotides/metabolism ; RNA/metabolism ; Tissue Distribution ; Transcription Factors/metabolism ; Cerebrospinal Fluid/chemistry ; Central Nervous System Diseases/therapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies